<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">680781</article-id><article-id pub-id-type="doi">10.26442/20751753.2025.4.203311</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The role of proinflammatory cytokines in the comprehensive treatment of patients with diabetic foot syndrome complicated by osteomyelitis</article-title><trans-title-group xml:lang="ru"><trans-title>Роль провоспалительных цитокинов в комплексном лечении больных с синдромом диабетической стопы, осложненным остеомиелитом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9442-5207</contrib-id><contrib-id contrib-id-type="spin">2745-5102</contrib-id><name-alternatives><name xml:lang="en"><surname>Lutsenko</surname><given-names>Yuri G.</given-names></name><name xml:lang="ru"><surname>Луценко</surname><given-names>Юрий Григорьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Assoc. Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доц. каф. хирургии фак-та непрерывного медицинского и фармацевтического образования</p></bio><email>karabak.igor@yandex.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-4534-7517</contrib-id><contrib-id contrib-id-type="spin">3827-7302</contrib-id><name-alternatives><name xml:lang="en"><surname>Karabak</surname><given-names>Igor S.</given-names></name><name xml:lang="ru"><surname>Карабак</surname><given-names>Игорь Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Surgeon</p></bio><bio xml:lang="ru"><p>врач-хирург хирургического отд-ния</p></bio><email>karabak.igor@yandex.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3370-0439</contrib-id><contrib-id contrib-id-type="spin">2859-9058</contrib-id><name-alternatives><name xml:lang="en"><surname>Andrienko</surname><given-names>Igor B.</given-names></name><name xml:lang="ru"><surname>Андриенко</surname><given-names>Игорь Борисович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Assoc. Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доц. каф. хирургии фак-та непрерывного медицинского и фармацевтического образования</p></bio><email>karabak.igor@yandex.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-1569-4669</contrib-id><name-alternatives><name xml:lang="en"><surname>Karabak</surname><given-names>Kirill S.</given-names></name><name xml:lang="ru"><surname>Карабак</surname><given-names>Кирилл Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Resident</p></bio><bio xml:lang="ru"><p>ординатор кафедры сердечно-сосудистой хирургии</p></bio><email>karabak.igor@yandex.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Gorky Donetsk State Medical University</institution></aff><aff><institution xml:lang="ru">Донецкий государственный медицинский университет им. М. Горького</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Donetsk Central City Clinical Hospital No. 9</institution></aff><aff><institution xml:lang="ru">Центральная городская клиническая больница №9 г. Донецка</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-04-25" publication-format="electronic"><day>25</day><month>04</month><year>2025</year></pub-date><volume>27</volume><issue>4</issue><issue-title xml:lang="en">Endocrinology</issue-title><issue-title xml:lang="ru">Эндокринология</issue-title><fpage>233</fpage><lpage>236</lpage><history><date date-type="received" iso-8601-date="2025-05-27"><day>27</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-06-16"><day>16</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/680781">https://consilium.orscience.ru/2075-1753/article/view/680781</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Diabetic foot syndrome (DFS) complicated by osteomyelitis is a severe consequence of diabetes mellitus, often leading to amputations. Chronic inflammation and cytokine imbalance (interleukin – IL-1β, 6, tumor necrosis factor – TNF-α) play a key role in pathogenesis, making the search for immunomodulatory therapies, such as ozone therapy (OT), highly relevant.</p> <p><bold>Aim.</bold> To study the role of proinflammatory cytokines in the complex treatment of patients with DFS complicated by osteomyelitis.</p> <p><bold>Materials and methods.</bold> The study included 62 patients with DFS complicated by osteomyelitis, divided into two groups: the main group (n = 31) received standard treatment supplemented with OT (intravenous infusions of ozonated saline) and ultrasonic cavitation (USC) of osteomyelitic lesions, while the control group (n = 31) received only standard treatment. Levels of IL-1β, TNF-α, and IL-6 were measured using Enzyme-Linked Immunosorbent Assay before treatment and on days 14–15.</p> <p><bold>Results.</bold> In the main group, levels of IL-1β, TNF-α and IL-6 decreased by 4.4, 10.24 and 3.2 times respectively (<italic>p</italic> &lt; 0.001). The frequency of postoperative complications (phlegmons) was lower in the main group (9.7% vs 22.6%; <italic>p</italic> = 0.04). The average hospitalization duration decreased from 20.3 ± 4.84 to 14.9 ± 2.08 days.</p> <p><bold>Conclusion.</bold> OT and USC demonstrated significant immunomodulatory effects, reducing pro-inflammatory cytokine levels and improving clinical outcomes. The inclusion of OT and USC in the comprehensive treatment of diabetic foot syndrome complicated by osteomyelitis is advisable to reduce healing time and complications.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Синдром диабетической стопы (СДС), осложненный остеомиелитом, является тяжелым последствием сахарного диабета, часто приводящим к ампутациям. Хроническое воспаление и дисбаланс цитокинов (интерлейкинов – ИЛ-1β и 6, фактора некроза опухоли α – ФНО-α) играют ключевую роль в патогенезе, что делает актуальным поиск методов иммуномодулирующей терапии, таких как озонотерапия (ОТ).</p> <p><bold>Цель.</bold> Изучить роль провоспалительных цитокинов в комплексном лечении больных с СДС, осложненным остеомиелитом.</p> <p><bold>Материалы и методы.</bold> В исследование включены 62 пациента с СДС, осложненным остеомиелитом, разделенные на 2 группы: основная (n = 31) получала стандартное лечение, дополненное ОТ (внутривенные инфузии озонированного физраствора) и ультразвуковой кавитацией (УЗК) очагов остеомиелита, группа сравнения (n = 31) – только стандартное лечение. Уровни ИЛ-1β, ФНО-α и ИЛ-6 измеряли методом ELISA (Enzyme-Linked Immunosorbent Assay) до лечения и на 14–15-е сутки после него.</p> <p><bold>Результаты.</bold> В основной группе уровни ИЛ-1β, ФНО-α и ИЛ-6 снизились в 4,4, 10,24 и 3,2 раза соответственно (<italic>p</italic> &lt; 0,001). Частота послеоперационных осложнений (флегмон) была ниже в основной группе (9,7% vs 22,6%; <italic>p</italic> = 0,04). Средняя продолжительность госпитализации сократилась с 20,3 ± 4,84 до 14,9 ± 2,08 дня.</p> <p><bold>Заключение.</bold> ОТ и УЗК продемонстрировали выраженное иммуномодулирующее действие, снижая уровень провоспалительных цитокинов и улучшая клинические исходы. Включение ОТ и УЗК в комплексное лечение СДС, осложненного остеомиелитом, целесообразно для сокращения сроков заживления и уменьшения осложнений.</p></trans-abstract><kwd-group xml:lang="en"><kwd>diabetic foot</kwd><kwd>osteomyelitis</kwd><kwd>cytokines</kwd><kwd>ozone therapy</kwd><kwd>ultrasonic cavitation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>диабетическая стопа</kwd><kwd>остеомиелит</kwd><kwd>цитокины</kwd><kwd>озонотерапия</kwd><kwd>ультразвуковая кавитация</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation, 2021. PMID:35914061</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Liu J, Ren ZH, Qiang H, et al. Trends in the incidence of diabetes mellitus: Results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20(1):1415. DOI:10.1186/s12889-020-09502-x</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790. DOI:10.1038/s41598-020-71908-9</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kerr M, Barron E, Chadwick P, et al. The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabet Med. 2019;36(8):995-1002. DOI:10.1111/dme.13973</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ernest HS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2020;344(12):907-16. DOI:10.1056/nejm200103223441207</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2020;15(6):985-95. DOI:10.1016/s1074-7613(01)00243-6</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Chada S, Sutton RB, Ekmekcioglu S, et al. MDA-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int Immunopharmacol. 2014;4(5):649-67. DOI:10.1016/j.intimp.2004.01.017</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Кисляков В.А., Оболенский В.Н., Юсупов И.А. Синдром диабетической стопы: комплексный подход к лечению. Русский медицинский журнал. 2015;12:768-70 [Kislyakov VA, Obolensky VN, Yusupov IA. Diabetic foot syndrome: An integrated approach to treatment. Russian Medical Journal. 2015;12:768-70 (in Russian)].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lipsky BA. Treating diabetic foot osteomyelitis primarily with surgery or antibiotics: have we answered the question? Diabetes Care. 2014;37:593-5. DOI:10.2337/dc13-2510</mixed-citation></ref></ref-list></back></article>
